BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Requests Further Data On Cilansetron, Solvay Pharmaceuticals, Inc.'s Proposed Treatment For Irritable Bowel Syndrome Wth Diarrhea Predominance (IBS-D)


10/19/2005 5:13:11 PM

MARIETTA, Ga., April 1 /PRNewswire/ -- As announced last week during a corporate press conference in Brussels, Solvay Pharmaceuticals, Inc. has received a letter from the Food and Drug Administration (FDA) on its new drug application (NDA) for cilansetron, a novel drug submitted to the Agency for the treatment of irritable bowel syndrome with diarrhea predominance (IBS-D) in both men and women. The "not-approvable" action letter requests additional clinical trials. Solvay Pharmaceuticals, Inc. is examining its options and will discuss future steps with the FDA and other experts for this product in the U.S.

About IBS-D

As many as 30-45 million North American adults have symptoms of IBS -- approximately one-third from IBS-D. The common symptoms of IBS-D are diarrhea, abdominal pain/discomfort, and fecal urgency. IBS has a significant negative impact on the quality of life for the many men and women who suffer from this condition, causing lost days of work and interfering with home- based, social and leisure activities.

About Solvay Pharmaceuticals, Inc.

Solvay Pharmaceuticals, Inc. (http://www.solvaypharmaceuticals-us.com/) of Marietta, Georgia (USA), is a research-driven pharmaceutical company that seeks to fulfill unmet medical needs in the therapeutic areas of cardiology, gastroenterology, mental health, women's health and a select group of specialized markets including men's health. It is a part of the global Solvay Pharmaceuticals organization whose core activities consist of discovering, developing and manufacturing medicines for human use. Solvay Pharmaceuticals, Inc. is a subsidiary corporation of the worldwide Solvay Group of chemical and pharmaceutical companies headquartered in Brussels, Belgium.

Solvay Pharmaceuticals, Inc.

CONTACT: Gabrielle Braswell, Assistant Director, Public Affairs, ofSolvay Pharmaceuticals, Inc., +1-770-578-5637, orgabrielle.braswell@solvay.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES